Kiniksa Pharmaceuticals International (KNSA) Q1 2026 earnings summary

Executive summary

• Q1 2026 ARCALYST net revenue reached $214.3 million, up 56% year-over-year, driven by strong commercial execution, new prescriber growth, and market adoption for recurrent pericarditis.

• Full-year 2026 revenue guidance was raised to $930–$945 million, reflecting robust market momentum and increased breadth and depth of prescribing.

• Advanced KPL-387 phase II/III clinical program in recurrent pericarditis, with phase II data expected in H2 2026 and phase III initiation by year-end; KPL-1161 phase I planned by end of 2026.

• Maintained strong financial position with $468.1 million in cash at quarter-end, no debt, and continued positive cash flow.

• Focused on developing and commercializing therapies for cardiovascular and autoimmune diseases, with ARCALYST as the lead product and a pipeline including KPL-387 and KPL-1161.

Financial highlights

• Net revenue for Q1 2026 was $214.3 million, up from $137.8 million in Q1 2025, driven by increased ARCALYST patient enrollment.

• Net income increased to $22.6 million in Q1 2026 from $8.5 million in Q1 2025.

• Total operating expenses rose to $185.0 million from $124.5 million year-over-year, reflecting higher collaboration, R&D, and SG&A costs.

• Cash, cash equivalents, and short-term investments stood at $468.1 million as of March 31, 2026.

• Net income per diluted share was $0.27, up from $0.11 in Q1 2025.

Outlook and guidance

• Full-year 2026 ARCALYST net product revenue guidance raised to $930–$945 million from prior $900–$920 million.

• Expect to remain cash flow positive on an annual basis under current operating plan.

• Phase II data for KPL-387 expected in H2 2026; phase III to start by year-end; KPL-1161 phase I study planned to start by end of 2026.

• Cash and expected inflows projected to fund operations and capital expenditures for at least the next 12 months.

• Anticipates continued significant expenses for ARCALYST commercialization, pipeline development, and potential strategic transactions.